74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Myriad Genetics Inc
Closed
Sector Healthcare
14.18 -5.4
Overview
Share price change
24h
Min
14.11
Max
14.25
Income | 15M -22M |
|---|---|
Sales | 1.8M 213M |
EPS | 0.06 |
Profit margin | -10.361 |
Employees | 2,700 |
EBITDA | 19M -2.2M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +27.93 upside |
Next Earnings | 24 Feb 2025 |
|---|
Market Cap | 218M 1.4B |
|---|---|
Previous open | 19.58 |
Previous close | 14.18 |
News Sentiment
By Acuity
62%
38%
340 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Myriad Genetics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Myriad Genetics Inc Forecast
Price Target
By TipRanks
27.93% upside
12 Months Forecast
Average 18.14 USD 27.93%
High 29 USD
Low 13 USD
Based on 7 Wall Street analysts offering 12 month price targets forMyriad Genetics Inc - Dist in the last 3 months.
Sentiment
By Acuity
340 / 393 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
